Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer

Abstract

Lysosome-associated protein transmembrane-4 beta (LAPTM4B) is a novel oncogene, which has been indicated to be dramatically overexpressed in various malignant tumors. The aims of this study were to detect LAPTM4B protein expression in patients with non-small cell lung cancer (NSCLC) and then analyze the relationships of LAPTM4B protein with clinicopathologic factors, tumor angiogenesis and prognosis with SPSS statistical software. Immunohistochemistry was used to examine the expression of LAPTM4B and CD34 proteins in NSCLC tissues, and its results showed that LAPTM4B protein expression in NSCLC tissues was significantly higher than that in normal lung tissues (P < 0.001). Of the186 NSCLC cases, 129 (69.35 %) had strong expression of LAPTM4B protein, which was associated with histopathologic differentiation (P = 0.017), lymph node metastasis (P = 0.001) and TNM stage (P = 0.046), as well as the microvessel density (MVD) (P = 0.019). Kaplan-Meier survival analysis revealed that patients with strong LAPM4B protein expression and high MVD might have poor overall survival (OS; P = 0.001, P = 0.002, respectively) and disease-free survival (DFS; P = 0.002, P = 0.038, respectively). Multivariate analysis demonstrated that LAPTM4B protein was an independent prognostic marker for OS and DFS of NSCLC patients (P = 0.037, P = 0.046, respectively). These findings illustrated that LAPTM4B protein was closely associated with NSCLC progression, angiogenesis and poor prognosis, suggesting that LAPTM4B protein could be applied not only in predicting patient's outcome, but also in antiangiogenic therapy as a possible novel target molecule.

Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients

“…Tang et al examined LAPTM4B and CD34 proteins in non-small cell lung cancer, and their results revealed that LAPTM4B might promote tumor progression by inducing tumor angiogenesis [24]. Meng et al indicated that the downregulation of LAPTM4B suppressed tumor migration and invasion and significantly decreased VEGF expression.…”

Lysosomal-associated Transmembrane Protein 4B (LAPTM4B) Decreases Transforming Growth Factor β1 (TGF-β1) Production in Human Regulatory T Cells

“…In tumors, it appears to play an oncogenic role. High LAPTM4B levels are associated with poor prognosis in many types of cancers (31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41), and in vitro and in vivo analyses of cells in which LAPTM4B was overexpressed or silenced indicate that LAPTM4B favors proliferation, migration, invasion, tumorigenesis, and metastasis (42,43). Two mechanisms by which LAPTM4B plays oncogenic roles have recently been identified.…”

LAPTM4B Down Regulation Inhibits the Proliferation, Invasion and Angiogenesis of HeLa Cells In Vitro

“…Tumor growth relies on new blood vessels. Tang et al have reported that the LAPTM4B protein is closely associated with progression and micro vessel density in the context of non-small cell lung cancer, suggesting that LAPTM4B could play an important role in tumor angiogenesis [10]. However, the exact study, an LAPTM4B blockade may play a direct role in the degradation of HIF-1 and the …”